HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Perrigo

This article was originally published in The Rose Sheet

Executive Summary

Perrigo: Sales for the private-label company rose 6% to $196.3 mil. in the third quarter (ended March 31). The company reported a 4% decline in personal care product sales, noting that that business "remains challenging." In an effort to restore profitably in its personal care segment, Perrigo has been eliminating low-volume SKUs and raising product prices to help counter increasing raw material cost over the past year. Net earnings for the company, including extraordinary costs of $263,000 for restructuring and $1.6 mil. for litigation, fell 6.9% to $10.6 mil...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS002826

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel